Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis

Lee,Eun‑Ji; Kim,Min  Hee; Kim,Ye‑Ryung; Park,Joo‑Won; Park,Woo‑Jae

doi:10.3892/ijmm.2017.3326

Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis

Authors:
- Eun‑Ji Lee
- Min Hee Kim
- Ye‑Ryung Kim
- Joo‑Won Park
- Woo‑Jae Park
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Gachon University, Incheon 21999, Republic of Korea, Department of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea
Published online on: December 15, 2017 https://doi.org/10.3892/ijmm.2017.3326
Pages: 1715-1723

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallstone disease is one of the most prevalent and costly gastrointestinal disorders worldwide. Gallstones are formed in the biliary system by cholesterol secretions in bile, which result from excess cholesterol, a deficiency in bile salts or a combination of the two. The present study examined the effects of proteasome inhibition on gallstone formation using the proteasome inhibitors bortezomib (BT) and carfilzomib (CF). C57BL/6J mice were fed a lithogenic diet to generate gallstones and injected with BT or CF for 12 weeks. After 12 weeks of the lithogenic diet, 8 out of the 10 mice in the control group had developed gallstones, whereas none of the mice who received proteasome inhibitors had developed gallstones. Notably, the expression of genes associated with cholesterol synthesis (sterol regulatory element‑binding protein‑2 and 3‑hydroxy‑3‑methylglutaryl‑CoA reductase), cholesterol secretion [ATP‑binding cassette subfamily G member 5 (ABCG5) and ABCG8] and bile acid synthesis [cytochrome P450 family 7 subfamily A member 1 (Cyp7a1), Cyp7b1, Cyp27a1 and Cyp8b1] was reduced in the livers of mice injected with BT or CF. Cyp7a1 encodes cholesterol 7α‑hydroxylase, the rate‑limiting enzyme in the synthesis of bile acid from cholesterol. The present study therefore measured the expression levels of transcription factors that are known to inhibit Cyp7a1 expression, namely farnesoid X receptor (FXR), pregnane X receptor (PXR) and small heterodimer partner (SHP). Although FXR, PXR and SHP expression was predicted to increase in the presence of proteasome inhibitors, the expression levels were actually reduced; thus, it was concluded that they were not involved in the proteasome inhibition‑induced regulation of Cyp7a1. Further investigation of the mitogen‑activated protein kinase and protein kinase A (PKA) signaling pathways in human hepatoma cells revealed that proteasome inhibition‑induced c‑Jun N‑terminal kinase (JNK) phosphorylation reduced CYP7A1 and CYP27A1 expression. In addition, reduced PKA phosphorylation as a result of proteasome inhibition regulated ABCG5 and ABCG8 expression. In conclusion, these findings suggest that proteasome inhibition regulates cholesterol and biliary metabolism via the JNK and PKA pathways, and is a promising therapeutic strategy to prevent gallstone disease.

View Figures

View References

1	Stinton LM and Shaffer EA: Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 6:172–187. 2012. View Article : Google Scholar : PubMed/NCBI
2	Kosters A, Jirsa M and Groen AK: Genetic background of cholesterol gallstone disease. Biochim Biophys Acta. 1637:1–19. 2003. View Article : Google Scholar : PubMed/NCBI
3	Portincasa P, Moschetta A and Palasciano G: Cholesterol gallstone disease. Lancet. 368:230–239. 2006. View Article : Google Scholar : PubMed/NCBI
4	Tao R, Xiong X, DePinho RA, Deng CX and Dong XC: Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6. J Lipid Res. 54:2745–2753. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chiang JY: Bile acids: regulation of synthesis. J Lipid Res. 50:1955–1966. 2009. View Article : Google Scholar : PubMed/NCBI
6	Van Erpecum KJ: Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 35:281–287. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ahmed MH, Hamad MA, Routh C and Connolly V: Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother. 12:2673–2681. 2011. View Article : Google Scholar : PubMed/NCBI
8	Merzon E, Weiss NS, Lustman AJ, Elhayani A, Dresner J and Vinker S: Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf. 9:539–543. 2010. View Article : Google Scholar : PubMed/NCBI
9	Cariati A and Piromalli E: Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother. 13:1223–1227. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kotb MA: Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci. 13:8882–8914. 2012. View Article : Google Scholar :
11	Adams J, Palombella VJ and Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 18:109–121. 2000. View Article : Google Scholar : PubMed/NCBI
12	Field-Smith A, Morgan GJ and Davies FE: Bortezomib (Velca-detrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag. 2:271–279. 2006. View Article : Google Scholar
13	Oliva J, French SW, Li J and Bardag-Gorce F: Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol. 93:26–34. 2012. View Article : Google Scholar : PubMed/NCBI
14	Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH and Gores GJ: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am J Physiol Gastrointest Liver Physiol. 291:G709–G716. 2006. View Article : Google Scholar : PubMed/NCBI
15	Park WJ, Kim SY, Kim YR and Park JW: Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription. Int J Mol Med. 37:613–622. 2016. View Article : Google Scholar : PubMed/NCBI
16	Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL and McConkey DJ: Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65:11658–11666. 2005. View Article : Google Scholar : PubMed/NCBI
17	Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, et al: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 5:665–675. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M and Motzer RJ: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 22:3720–3725. 2004. View Article : Google Scholar : PubMed/NCBI
19	Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 22:2108–2121. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dick LR and Fleming PE: Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 15:243–249. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Wooton-Kee CR, Coy DJ, Athippozhy AT, Zhao T, Jones BR and Vore M: Mechanisms for increased expression of cholesterol 7alpha-hydroxylase (Cyp7a1) in lactating rats. Hepatology. 51:277–285. 2010. View Article : Google Scholar
23	Gupta S, Stravitz RT, Dent P and Hylemon PB: Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem. 276:15816–15822. 2001. View Article : Google Scholar : PubMed/NCBI
24	Stroup D: Kinase/phosphatase regulation of CYP7A1. Front Biosci. 10:1678–1692. 2005. View Article : Google Scholar : PubMed/NCBI
25	Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H and Mangelsdorf DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 277:18793–18800. 2002. View Article : Google Scholar : PubMed/NCBI
26	Yamazaki Y, Yasui K, Hashizume T, Suto A, Mori A, Murata Y, Yamaguchi M, Ikari A and Sugatani J: Involvement of a cyclic adenosine monophosphate-dependent signal in the diet-induced canalicular trafficking of adenosine triphosphate-binding cassette transporter g5/g8. Hepatology. 62:1215–1226. 2015. View Article : Google Scholar : PubMed/NCBI
27	Moschetta A, Bookout AL and Mangelsdorf DJ: Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 10:1352–1358. 2004. View Article : Google Scholar : PubMed/NCBI
28	Bertolotti M, Gabbi C, Anzivino C, Carulli L and Carulli N: Changes in bile acid synthesis in gallstone disease: cause, consequence, or neither? Hepatology. 46:1664–1665. 2007. View Article : Google Scholar : PubMed/NCBI
29	Li T, Jahan A and Chiang JY: Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology. 43:1202–1210. 2006. View Article : Google Scholar : PubMed/NCBI
30	Liu X, Qi Y, Tian B, Chen D, Gao H, Xi C, Xing Y and Yuan Z: Maternal protein restriction induces alterations in hepatic tumor necrosis factor-α/CYP7A1 signaling and disorders regulation of cholesterol metabolism in the adult rat offspring. J Clin Biochem Nutr. 55:40–47. 2014. View Article : Google Scholar : PubMed/NCBI
31	Choi CH, Lee BH, Ahn SG and Oh SH: Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3β. Biochem Biophys Res Commun. 418:759–764. 2012. View Article : Google Scholar : PubMed/NCBI
32	Wang HQ, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY and Du ZX: Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression. Br J Pharmacol. 158:1405–1412. 2009. View Article : Google Scholar : PubMed/NCBI
33	Uppal H, Zhai Y, Gangopadhyay A, Khadem S, Ren S, Moser JA and Xie W: Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology. 47:1331–1342. 2008. View Article : Google Scholar : PubMed/NCBI
34	Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ and Kudlow JE: Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem. 282:22460–22471. 2007. View Article : Google Scholar : PubMed/NCBI
35	Hegde AN, Goldberg AL and Schwartz JH: Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. Proc Natl Acad Sci USA. 90:7436–7440. 1993. View Article : Google Scholar : PubMed/NCBI
36	Lin JT, Chang WC, Chen HM, Lai HL, Chen CY, Tao MH and Chern Y: Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Mol Cell Biol. 33:1073–1084. 2013. View Article : Google Scholar : PubMed/NCBI
37	Takenokuchi M, Miyamoto K, Saigo K and Taniguchi T: Bortezomib causes ER stress-related death of acute promyelocytic leukemia cells through excessive accumulation of PML-RARA. Anticancer Res. 35:3307–3316. 2015.PubMed/NCBI
38	Meregalli C, Carozzi VA, Sala B, Chiorazzi A, Canta A, Oggioni N, Rodriguez-Menendez V, Ballarini E, Ceresa C, Nicolini G, et al: Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice. J Biol Regul Homeost Agents. 29:115–124. 2015.PubMed/NCBI
39	Liu G, Friggeri A, Yang Y, Park Y-J, Tsuruta Y and Abraham E: miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci USA. 106:15819–15824. 2009. View Article : Google Scholar : PubMed/NCBI